BLOOMBERG : ¿ IAG Podría PAGAR DIVIDENDO A FINALES DE AÑO 2024 ? . The Owner Of BRITISH AIRWAYS Has Told Investors That Payouts Could Be Made Before The End Of the Year, Said The People , Asking Not To Be Identified Because The discussions Are Private .

 

GLAZMANN ( GRÍFOLS ) Da la Cara y Defiende en una Carta a los Accionistas la Actuación de la Compañía Ante el " Ataque " de Gotham . Grifols Prevé Cerrar en Junio la Venta del 20% de SHANGHAI RAAS ... ¿ COINCIDIENDO CON LA JUNTA DE ACCIONISTAS ... ?

Los Resultados de IAG Vuelan Más Alto Que los de Air France , KLM y Lufthansa . En la Junta de Accionistas se Pondrá Fecha al Retorno del Dividendo.

 

PharmaMar Rebota Desde los 27 euros ... Tan Solo Dos Cuestiones No Encajan ... Se Trata de Subidas en la Rectas Finales de Mercado y Sin Volumen ... y Sin Que se Despeine el Fondo Bajista Arrowstreet Capital, Limited Partnership .

 

IAG en el Primer Trimestre 2024 Ha Obtenido 540 Millones Más Versus Primer Trimestre 2023 . Un EBITDA de 68 Vs 9 . IAG Para Verano está Muy Bien Posicionada . XTB Da un Precio Objetivo de 2,50 euros .

 

Los Resultados están Por encima de las Previsiones del Mercado, Ya Que el Consenso de los Analistas Recogidos en Bloomberg Auguraba unas Pérdidas de 108 Millones de euros .

SN BIOSCIENCE RECEIVES FDA FAST TRACK DESIGNATION FOR SNB-101 FOR SMALL CELL LUNG CÁNCER ... Lo Que Sienta las Bases Para Poder Comercializarlo Inmediatamente Después de Completar los Ensayos Clínicos de FASE II . Por Recordar También Tiene el Status de ORPHAN DRUG .

 

PR NEWSWIRE .

SEOUL, South Korea , May 9, 2024 /PRNewswire/ -- SN Bioscience Co. Ltd. (CEO Park Young -hwan) announced on May 7 that the FDA has Granted FAST TRACK Designation for small cell lung cancer (SCLC) for SNB-101 (API: SN-38), a New Drug For Polymer Nanoparticle Anticancer under Clinical Trial . 

SNB-101 was designated as an ORPHAN DRUG for SMALL CELL LUNG CÁNCER and Pancreatic Cancer in July of last Year and February of This Year, Respectively . By Receiving FAST-TRACK designation this time, it is Evaluated That it Has laid the Groundwork That Can Be Commercialized Immediately After Completion of PHASE II CLINICAL TRIALS .

Despite a long period of REsearch and Development, SCLC still remains a field with high medical Unmet Needs . Currently, the FIRST-LINE STANDARD Treatment is a Combination Therapy of CISPLATIN And ETOPÓSIDE, a classic cytotoxic Anticancer Drug, and ' CLINICAL TRIALS ' are included as SECOND-LINE Treatments in the NCCN GUIDELINES .

FAST TRACK is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need . The FAST TRACK Designation facilitates the interactions with the FDA and allows a Rolling REVIEW For the Submission Package so it can be Reviewed in each section, rather than waiting until every section of the NDA is Completed . Additionally, it May Be Possible To Apply For ACCELERATED APPROVAL After The Completion of PHASE II CLINICAL TRIALS and PRIORITY REVIEW Immediately After The Completion of PHASE III  CLINICAL TRIALS When Qualified . ...